Lucira Health (NASDAQ:LHDXQ – Get Rating) is one of 41 publicly-traded companies in the "Diagnostic substances" industry, but how does it contrast to its peers? We will compare Lucira Health to similar businesses based on the strength of its dividends, analyst recommendations, institutional ownership, valuation, risk, profitability and earnings.
Analyst Recommendations
This is a summary of recent ratings for Lucira Health and its peers, as provided by MarketBeat.
Get Lucira Health alerts:| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lucira Health | 0 | 0 | 0 | 0 | N/A |
| Lucira Health Competitors | 365 | 629 | 1235 | 19 | 2.40 |
As a group, "Diagnostic substances" companies have a potential upside of 33.93%. Given Lucira Health's peers higher possible upside, analysts plainly believe Lucira Health has less favorable growth aspects than its peers.
Earnings & Valuation
This table compares Lucira Health and its peers gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Lucira Health | $93.06 million | -$64.83 million | -0.03 |
| Lucira Health Competitors | $480.44 million | $10.72 million | -52.66 |
Lucira Health's peers have higher revenue and earnings than Lucira Health. Lucira Health is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Insider and Institutional Ownership
57.0% of Lucira Health shares are held by institutional investors. Comparatively, 46.6% of shares of all "Diagnostic substances" companies are held by institutional investors. 30.4% of Lucira Health shares are held by company insiders. Comparatively, 14.1% of shares of all "Diagnostic substances" companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares Lucira Health and its peers' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lucira Health | -67.54% | -13.55% | -8.47% |
| Lucira Health Competitors | -802.63% | -114.55% | -27.76% |
Risk and Volatility
Lucira Health has a beta of 3.36, indicating that its share price is 236% more volatile than the S&P 500. Comparatively, Lucira Health's peers have a beta of 1.37, indicating that their average share price is 37% more volatile than the S&P 500.
Summary
Lucira Health beats its peers on 7 of the 10 factors compared.
About Lucira Health
(Get Rating)
Lucira Health Inc. is a medical technology company. It is focused on the development and commercialization of transformative and infectious disease test kits. Lucira Health Inc. is based in Emeryville, California.
Receive News & Ratings for Lucira Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucira Health and related companies with MarketBeat.com's FREE daily email newsletter.